trending Market Intelligence /marketintelligence/en/news-insights/trending/2G5EGmClAnF6u1s5FW89Wg2 content esgSubNav
In This List

BeyondSpring drug helped prevent chemotherapy side effect in trial

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


BeyondSpring drug helped prevent chemotherapy side effect in trial

BeyondSpring Inc.'s plinabulin helped limit a chemotherapy-induced reduction in certain white blood cells, meeting the primary goal of the phase 2 portion of a phase 2/3 trial.

The study compared plinabulin to Amgen Inc.'s Neulasta, also known as pegfilgrastim, in the prevention of a side effect of docetaxel chemotherapy known as neutropenia, or an abnormally low count of neutrophil cells.

The primary goal of the trial was the number of days patients experienced severe or grade 4 neutropenia, which was measured by neutrophil count.

The initial results from the phase 2 portion will be presented at a medical meeting in San Francisco in January 2018, and the phase 3 part of the trial will begin soon, BeyondSpring said.